Abstract
AbstractIgE is central to the development of allergic diseases, and its neutralization alleviates allergic symptoms. However, most of these antibodies are based on IgG1, which is associated with an increased risk of fragment crystallizable-mediated side effects. Moreover, omalizumab, an anti-IgE antibody approved for therapeutic use, has limited benefits for patients with high IgE levels. Here, we assess a fusion protein with extracellular domain of high affinity IgE receptor, FcεRIα, linked to a IgD/IgG4 hybrid Fc domain we term IgETRAP, to reduce the risk of IgG1 Fc-mediated side effects. IgETRAP shows enhanced IgE binding affinity compared to omalizumab. We also see an enhanced therapeutic effect of IgETRAP in food allergy models when combined with Bifidobacterium longum, which results in mast cell number and free IgE levels. The combination of IgETRAP and B. longum may therefore represent a potent treatment for allergic patients with high IgE levels.
Funder
Rural Development Administration
Ministry of Health and Welfare
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference64 articles.
1. XOLAIR-Allergic Asthma, CSU & Nasal Polyps Treatment, https://www.xolairhcp.com/. (Access date: 2022. June. 29).
2. Wang, H. H., Li, Y. C. & Huang, Y. C. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J. Allergy Clin. Immunol. 138, 1719–1722 e1711 (2016).
3. Finkelman, F. D. Anaphylaxis: lessons from mouse models. J. Allergy Clin. Immunol. 120, 506–515 (2007).
4. Finkelman, F. D., Khodoun, M. V. & Strait, R. Human IgE-independent systemic anaphylaxis. J. Allergy Clin. Immunol. 137, 1674–1680 (2016).
5. Reber, L. L., Hernandez, J. D. & Galli, S. J. The pathophysiology of anaphylaxis. J. Allergy Clin. Immunol. 140, 335–348 (2017).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献